EUCTR2010-021850-20-IT进行中（未招募）不适用
A Phase 3, Multicenter, Double-blind, Placebo-controlled Randomized Discontinuation Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4-Diaminopyridine Phosphate) in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •=18 years of age. - Confirmed diagnosis of LEMS as documented by acquired (typical) proximal muscle weakness and at least 1 of the following: Nerve conduction findings (CMAP that increases at least 2-fold after maximum voluntary contraction of the tested muscle) Positive anti-P/Q type voltage-gated calcium-channel antibody test - If currently receiving treatment with amifampridine for LEMS, a normal resp function as deined by an FVC >= 80% of predicted - If not currently receving amifampridine and pt has no history of othr current respiratory disease a FVC >= 60& i predicted- Completion of anti-cancer treatment at least 3 months (90 days) prior to Screening - A QMG score of = 5 is required for patients without any prior symptomatic treatment for LEMS - If currently receiving treatment for LEMS, patients must present with some signs and/or symptoms consistent with LEMS - Normal respiratory function as defined by a forced vital capacity > 80% predicted (score of 0 on this dimension of QMG) - Normal swallowing function as defined by the ability to swallow 4 ounces of water without coughing or throat clearing (score of 0 on this dimension of QMG) - If receiving peripherally acting cholinesterase inhibitors (eg, pyridostigmine), a stable dose of cholinesterase inhibitors is required for at least 7 days prior to Screening - If receiving permitted oral immunosuppressants (eg, prednisone or other corticosteroid, azathioprine, mycophenolate), a stable dose is required for at least 90 days prior to Screening - Negative pregnancy test for females of childbearing potential at Screening - If sexually active, willing to use 2 acceptable methods of contraception from Screening until 3 months after the last dose - Willing to perform all study procedures as physically possible - Willing and able to provide written informed consent after the nature of the study has been explained and prior to the start of any research-related procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •History of epilepsy or seizure - Known active brain metastasis - cuncurrent use of fampridine and ay other 3,4 diaminopridine other than IP provided - - Use of medications known to lower the epileptic threshold within 7 days or 5 half-lives, whichever is longer, prior to Screening - Use of medications which inhibit neuromuscular junction function within 7 days or 5 half-lives, whichever is longer, prior to Screening - Use of IVIG, plasmapheresis (plasma exchange), or immunoadsorption within 90 days prior to Screening - Use of guanidine hydrochloride within 7 days of Screening - Use of rituximab within 12 months prior to Screening - History of drug allergy to any pyridine-containing substances or any amifampridine phosphate excipient(s) - Use of any other investigational product other than amifampridine phosphate or investigational medical device within 30 days prior to Screening or requirement for any investigational agent prior to completion of all scheduled study assessments - Treatment with a concomitant medication that prolongs the QT wave QT/QTc wave corrected for heart rate (QTc) interval within 7 days or 5 half-lives, whichever is longer, prior to Screening - Treatment with sultopride within 7 days prior to Screening - sinus arrhythmias - excessive heart rate variation at rest -QT wave corrected for heart rate using Bazzzatt`s formula (QTBC) interval > 450 msec confirmed by a rpeat ECG - PR inteval > 210 msec - QRS interval > 120 msec - Early polarisation pattern that increase the risk of partecipating in the study - Documented history of arrhythmias - Breastfeeding or pregnant at Screening or planning to become pregnant (self or partner) at any time during the study. Male patients with breastfeeding partners are not excluded from the study - Likely or expected to require treatment for cancer within 3 months (90 days) after entering Screening - History of severe renal impairment or evidence of severe renal impairment on Screening laboratory tests- Screening laboratory tests for hepatic impairment; In pt with without cancer , ALT, AST and or total bilirubin >ULN - in pt with cancer ALT, AST > 5xupper limit of normal (ULN) and or total bilirubin > 3 x ULN History of uncontrolled asmtma - Basline vital capacity < 1500 ml
研究者
相似试验
进行中（未招募）
不适用
A study to examine the maintenance of study drug, SPD489, in adults subjects who are suffering from Binge Eating DisorderEUCTR2012-004457-88-SEShire Development LLC412
进行中（未招募）
1 期
A study to examine the maintenance of study drug, SPD489, in adults subjects who are suffering from Binge Eating DisorderEUCTR2012-004457-88-DEShire Development LLC412
进行中（未招募）
不适用
A study to examine the maintenance of study drug, SPD489, in adults subjects who are suffering from Binge Eating DisorderBinge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss behaviors of bulimia nervosa. In May 2013, BED was formally added as a free standing diagnosis under DSM-5.EUCTR2012-004457-88-ESShire Development LLC412
进行中（未招募）
1 期
A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney Disease (ADPKD)MedDRA version: 8.1 Level: LLT Classification code 10036046 Term: Polycystic kidney, autosomal dominantEUCTR2006-002768-24-GBOtsuka Pharmaceutical Development & Commercialization, Inc.1,500
进行中（未招募）
不适用
A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney Disease (ADPKD)MedDRA version: 8.1Level: LLTClassification code 10036046Term: Polycystic kidney, autosomal dominantEUCTR2006-002768-24-DEOtsuka Pharmaceutical Development & Commercialization, Inc.1,500